Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor-Based Dual Antiplatelet Therapy in Coronary Artery Bypass Grafting
NCT06981390Not yet recruiting
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ticagrelor in coronary artery disease (CAD) (3 arms). Primary endpoint: Saphenous Vein Graft Patency at 12 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06981390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981390.